AstraZeneca Chief Executive Pascal Soriot, fearing a potentially abrupt Brexit, said on Saturday that lack of progress in negotiations made it impossible for him to sign a public letter of support for the British government’s strategy.
As reported by Reuters this week, Prime Minister Theresa May’s office has asked companies listed in the blue-chip FTSE 100 index to put their name to a public letter welcoming the government’s efforts to make Brexit a success.
“The reason I didn’t sign is that I felt there are so many areas that are still uncertain. How can we support something that we don’t really understand fully?” Soriot told Reuters on the sidelines of a cancer conference in Madrid.
Executives at several companies have said privately that the request went down badly with many large corporations but they have been reluctant to comment publicly.
Soriot said his refusal to sign did not mean the drugmaker disagreed with Britain’s decision to leave the European Union, adding that it could have some positive aspects if it went hand-in-hand with increased support for the UK life sciences sector.
But the deep uncertainty about future terms of trade just 18 months before Brexit happens in March 2019 means exports of medicines could be hampered, he said.
“What is starting to worry me, I must say, is the potential for the one thing I didn’t think would happen which is a hard Brexit,” he said.
“If there is no extension we will be left in limbo because the UK will come out of Europe and we will have no trade agreements.”
Britain’s second-biggest pharmaceuticals company makes a large amount of products in the north of England, including the cancer drug Zoladex, sales of which are increasing rapidly in China and other countries around the world.
“We need to know that is not going to be disrupted because right now we are exporting under a trade agreement between the EU and China,” Soriot said.
Many companies fear that Britain’s move to leave the world’s largest trading bloc will increase bureaucracy, drive up costs and eat into profitability.
The public letter, which May’s advisers wanted Soriot and other business leaders to sign, states that signatories are confident that “global Britain has the potential to become one of the most productive economies of the 21st century”.
By Ben Hirschler
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.